Propafenone-induced drug fever in the absence of agranulocytosis
- PMID: 9220185
- PMCID: PMC6655438
- DOI: 10.1002/clc.4960200715
Propafenone-induced drug fever in the absence of agranulocytosis
Abstract
Propafenone is an antiarrhythmic drug used in the treatment of life-threatening ventricular tachyarrhythmias. Adverse reactions necessitating discontinuation of the medication are common. Propafenone-induced drug fever has not been definitively proven. We present a case report of drug fever secondary to propafenone, confirmed with rechallenge.
References
-
- Physicians' Desk Reference, 50th edition, p. 1352–1355. Montvale, NJ: Medical Economics Company, 1996.
-
- Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias‐Mano D, Barker AH, Arensberg D, Baker A, Friedman L, Greene HL, Huther ML, Richardson DW, and the CAST Investigators : Mortality and morbidity in patients receiving encainide, flecanide or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991; 324: 781–788 - PubMed
-
- The Cardiac Arrhythmia Suppression Trial II Investigators : Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 1992; 327: 227–233 - PubMed
-
- Reynolds JEF. (Ed): Martindale: The Extra Pharmacopoeia. 31st edition, p. 935–936. London: Pharmaceutical Press, 1996.
-
- Bryson HM, Palmer KJ, Langtry HD, Fitton A: Propafenone: A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in cardiac arrhythmias. Drugs 1993; 45: 85–130 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
